Remote video URL
Your peers rated this 4 stars
23-minute watch | Talk 1 of 4

EHA: Follow the patient pathway to survival in 2L DLBCL

Planning ahead for 2L

Dr Mariana Bastos-Oreiro
Gregorio Marañón University Hospital & Complutense University, Madrid, Spain

Prof. Graham Collins
Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Dr Mariana Bastos-Oreiro of the Gregorio Marañón University Hospital & Complutense University, Madrid,
Spain and Prof. Graham Collins of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK provide
an overview of patient identification and planning ahead for CAR T in 2L DLBCL

Read more

Talks in this series

23-minute watch | Talk 1 of 4
EHA: Follow the patient pathway to survival in 2L DLBCL
23-minute watch
EHA: Follow the patient pathway to survival in 2L DLBCL

Planning ahead for 2L

10-minute watch | Talk 3 of 4
23-minute watch | Talk 1 of 4
EHA: Follow the patient pathway to survival in 2L DLBCL
23-minute watch
EHA: Follow the patient pathway to survival in 2L DLBCL

Planning ahead for 2L

Interested in this topic?

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In the United Kingdom, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.